Role of nicotine receptor partial agonists in tobacco cessation

Indian Journal of Psychiatry

Volumn 56, Issue 1, 2014, Pages 17-23

  Maity, Nivedita ^a   Chand, Prabhat ^b   Murthy, Pratima ^b  

^a M S RAMAIAH MEDICAL COLLEGE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Cessation; cytisine; tobacco dependence; varenicline

Indexed keywords

AMFEBUTAMONE; COTININE; CYTISINE; DIANICLINE; NICOTINE; NICOTINE GUM; NICOTINIC AGENT; NICOTINIC RECEPTOR; NORTRIPTYLINE; PLACEBO; TOBACCO SMOKE; VARENICLINE;

CLINICAL STUDY; CONGESTIVE HEART FAILURE; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; META ANALYSIS (TOPIC); NICOTINE REPLACEMENT THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW (TOPIC); TOBACCO DEPENDENCE; TOBACCO USE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 84892724781     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.124709     Document Type: Review

References (47)

1. Jha P, Jacob B, Gajalakshmi V, Gupta PC, Dhingra N, Kumar R, et al. A nationally representative case-control study of smoking and death in India. N Engl J Med 2008; 358: 1137-47.
2. Gajalakshmi V, Peto R, Kanaka TS, Jha P. Smoking and mortality from tuberculosis and other diseases in India: Retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003; 362: 507-15.
3. Rastogi T, Jha P, Reddy KS, Prabhakaran D, Spiegelman D, Stampfer MJ, et al. Bidi and cigarette smoking and risk of acute myocardial infarction among males in urban India. Tob Control 2005; 14: 356-8.
4. Murthy P, Saddichha S. Tobacco cessation services in India: Recent developments and the need for expansion. Indian J Cancer 2010; 47 Suppl 1: 69-74.
5. Services USDoHaH. The Health Consequences of Smoking: A Report of the Surgeon General. Washington, US: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
6. Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA 2012; 308: 1573-80.
7. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U. S. Public Health Service Clinical Practice Guideline executive summary. Respir Care 2008; 53: 1217-22.
8. Aveyard P, West R. Cytisine and the failure to market and regulate for human health. Thorax 2013; 68: 989.
9. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: Systematic review and meta-analysis. Thorax 2013; 68: 1037-42.
10. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011; 2: CD006103.
11. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012; 4: CD006103.
12. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: An overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5: CD009329.
13. Berrendero F, Robledo P, Trigo JM, Martín-García E, Maldonado R. Neurobiological mechanisms involved in nicotine dependence and reward: Participation of the endogenous opioid system. Neurosci Biobehav Rev 2010; 35: 220-31.
14. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev 2009; 89: 73-120.
15. Benowitz NL. Pharmacology of nicotine: Addiction and therapeutics. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.
16. Benowitz NL. Nicotine addiction. N Engl J Med 2010; 362: 2295-303.
17. Etter JF. Cytisine for smoking cessation: A literature review and a meta-analysis. Arch Intern Med 2006; 166: 1553-9.
18. Kotz D, Brown J, West R. Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: Evidence from an English population study. Psychopharmacology (Berl) 2013; 231: 37-42.
19. Kralikova E, Kmetova A, Stepankova L, Zvolska K, Davis R, West R. Fifty-two-week continuous abstinence rates of smokers being treated with varenicline versus nicotine replacement therapy. Addiction 2013; 108: 1497-502.
20. Wang C, Cho B, Xiao D, Wajsbrot D, Park PW. Effectiveness and safety of varenicline as an aid to smoking cessation: Results of an inter-Asian observational study in real-world clinical practice. Int J Clin Pract 2013; 67: 469-76.
21. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 2010; 49: 799-816.
22. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: A cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.
23. Tonstad S, Davies S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: A pooled analysis. Drug Saf 2010; 33: 289-301.
24. Aveyard P, McRobbie H, Stapleton J, West R. Varenicline: Effectiveness and safety. National Centre for Smoking Cessation and Training, 2012.
25. Gibbons RD, Mann JJ. Varenicline, smoking cessation, and neuropsychiatric adverse events. Am J Psychiatry 2013; 170: 1460-7.
26. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ 2011; 183: 1359-66.
27. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: Systematic review and meta-analysis. BMJ 2012; 344: e2856.
28. Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ 2013; 347: f5198.
29. Rasmussen T, Swedberg MD. Reinforcing effects of nicotinic compounds: Intravenous self-administration in drug-naive mice. Pharmacol Biochem Behav 1998; 60: 567-73.
30. Scharfenberg G, Benndorf S, Kempe G. Cytisine (Tabex) as a pharmaceutical aid in stopping smoking. Dtsch Gesundheitsw 1971; 26: 463-5.
31. Paun D, Franze J. Breaking the smoking habit using cytisin containing "Tabex" tablets. Dtsch Gesundheitsw 1968; 23: 2088-91.
32. Stoyanov S, Yanachkova M. Tabex-therapeutic efficacy and tolerance. Savr Med 1972; 6: 31-3.
33. Stoyanov S, Yanachkova M. Treatment of nicotinism with the Bulgarian drug Tabex. Chimpharm 1965; 2: 13.
34. Bennodorf S, Kempe G, Scharfenberg G, Wendekamm R, Winkelvoss E. Results of the smoking-habit breaking using cytisin (Tabex). I. Dtsch Gesundheitsw 1968; 23: 2092-6.
35. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011; 365: 1193-200.
36. Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 2008; 3: 57-62.
37. Jain R, Jhanjee S, Jain V, Gupta T, Mittal S, Goelz P, et al. A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. Nicotine Tob Res 2014; 16: 50-7.
38. Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: Randomised double blind placebo controlled trial. BMJ 2010; 341: c6549.
39. Kotz D, Fidler J, West R. Very low rate and light smokers: Smoking patterns and cessation-related behaviour in England, 2006-11. Addiction 2012; 107: 995-1002.
40. de Dios MA, Anderson BJ, Stanton C, Audet DA, Stein M. Project Impact: A pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. J Subst Abuse Treat 2012; 43: 322-30.
41. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 2011; 139: 591-9.
42. Tønnesen P. Smoking cessation and COPD. Eur Respir Rev 2013; 22: 37-43.
43. Williams JM. Varenicline should be used as a first-line treatment to help smokers with mental illness quit. J Dual Diagn 2012; 8: 113-6.
44. Thirthalli J, Chand PK. The implications of medication development in the treatment of substance use disorders in developing countries. Curr Opin Psychiatry 2009; 22: 274-80.
45. Catlin A, Cowan C, Heffler S, Washington B, National Health Expenditure Accounts Team. National health spending in 2005: The slowdown continues. Health Aff (Millwood) 2007; 26: 142-53.
46. Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: A literature review. P T 2012; 37: 45-55.
47. Keating GM, Lyseng-Williamson KA. Varenicline: A pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010; 28: 231-54.